Posted in | News | Nanomedicine

AACR Annual Meeting: Three Abstracts on BIND Therapeutics’s Accurins to be Presented

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia.

The abstracts were published online at www.aacr.org.

"We are very pleased with the high quality of our data being presented at AACR and believe these data further validate the ability of our Accurins to control the biodistribution of therapeutic payloads and target diseased cells while minimizing on target but off tissue toxicities, thereby creating the potential for best-in-class therapeutics," said Andrew Hirsch, president and chief executive officer of BIND. "The posters also reflect our commitment to creating innovative collaborations with leading biopharmaceutical companies to augment our internal pipeline and fully leverage our proprietary nanomedicine platform."

The posters will include preclinical and clinical pharmacokinetic data from BIND’s lead Accurin compound, BIND-014, and preclinical data from BIND’s collaboration with AstraZeneca on the Aurora B kinase inhibitor Accurin-AZD1152HQPA (AZD2811).

Poster presentations at AACR include the following:

BIND-014

  • Poster title: Pharmacokinetic of BIND-014 (docetaxel nanoparticles for injectable suspension) in preclinical species and patients with advanced solid tumors (Abstract #5514, Poster board #2)
  • Date/time: April 22, 2015; 8 am – 12 pm EDT
  • Poster session category: Chemistry
  • Location: Poster section 36

Accurin AZD1152HQPA (AZD2811)

  • Collaborator: AstraZeneca
  • Poster Title: AZD1152HQPA Accurin nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer (Abstract #3102, Poster board #15)
  • Date/time: April 21, 2015; 8 am – 12 pm EDT
  • Poster session category: Molecular and Cellular Biology
  • Location: Poster section 9
  • Poster Title: Imaging AZD1152HQPA Accurin nanoparticle accumulation in preclinical tumors (Abstract #3678, Poster board #11)
  • Date/time: April 21, 2015; 8 am – 12 pm EDT
  • Poster session category: Chemistry
  • Location: Poster section 35

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.